Global Molecular Biology Enzymes and Kits & Reagents Market

1 INTRODUCTION OF GLOBAL MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET OUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework

5 GLOBAL MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET, BY APPLICATION
5.1 Overview
5.2 Polymerase Chain Reaction
5.3 Sequencing
5.4 Cloning
5.5 Epigenetics
5.6 Restriction Digestion
5.7 Synthetic Biology
5.8 Other Applications

6 GLOBAL MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET, BY PRODUCT
6.1 Overview
6.2 Kits and Reagents
6.3 Enzymes
6.3.1 Polymerases
6.3.2 Ligases
6.3.3 Restriction Endonucleases
6.3.4 Reverse Transcriptases
6.3.5 Phosphatases
6.3.6 Proteases and Proteinases
6.3.7 Other Enzymes

7 GLOBAL MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET, BY END USER
7.1 Overview
7.2 Academic & Research Institutes
7.3 Pharmaceutical & Biotechnology Companies
7.4 Hospitals & Diagnostic Centers
7.5 Other End Users

8 GLOBAL MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKET, BY GEOGRAPHY
8.1 Overview
8.2 North America Regional Market Estimates and Forecasts, 2012 - 2025
8.2.1 U.S.
8.2.2 Canada
8.2.3 Mexico
8.3 Europe Regional Market Estimates and Forecasts, 2012 - 2025
8.3.1 Germany
8.3.2 U.K.
8.3.3 France
8.3.4 Rest of Europe
8.4 Asia Pacific Regional Market Estimates and Forecasts, 2012 - 2025
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Rest of Asia Pacific
8.5 Latin America Regional Market Estimates and Forecasts, 2012 - 2025
8.5.1 Brazil
8.5.2 Argentina
8.6 Rest of the World Regional Market Estimates and Forecasts, 2012 â€" 2025

9 GLOBAL MOLECULAR BIOLOGY ENZYMES AND KITS & REAGENTS MARKETCOMPETITIVE LANDSCAPE
9.1 Overview
9.2 Company Market Share
9.3 Vendor Landscape
9.4 Key Development Strategies

10 COMPANY PROFILES
10.1 Thermo Fisher Scientific, Inc.
10.1.1 Overview
10.1.2 Financial Performance
10.1.3 Product Outlook
10.1.4 Key Developments

10.2 Merck KGaA
10.2.1 Overview
10.2.2 Financial Performance
10.2.3 Product Outlook
10.2.4 Key Developments

10.3 Promega Corporation
10.3.1 Overview
10.3.2 Financial Performance
10.3.3 Product Outlook
10.3.4 Key Developments

10.4 New England Biolabs
10.4.1 Overview
10.4.2 Financial Performance
10.4.3 Product Outlook
10.4.4 Key Developments

10.5 Illumina, Inc.
10.5.1 Overview
10.5.2 Financial Performance
10.5.3 Product Outlook
10.5.4 Key Developments

10.6 Takara Bio, Inc.
10.6.1 Overview
10.6.2 Financial Performance
10.6.3 Product Outlook
10.6.4 Key Developments

10.7 Qiagen N.V.
10.7.1 Overview
10.7.2 Financial Performance
10.7.3 Product Outlook
10.7.4 Key Developments

10.8 Agilent Technologies, Inc.
10.8.1 Overview
10.8.2 Financial Performance
10.8.3 Product Outlook
10.8.4 Key Developments

10.9 F. Hoffmann-La Roche Ltd
10.9.1 Overview
10.9.2 Financial Performance
10.9.3 Product Outlook
10.9.4 Key Developments

10.10 Bio Basic Inc.
10.10.1 Overview
10.10.2 Financial Performance
10.10.3 Product Outlook
10.10.4 Key Developments

10.11 Jena Bioscience GmbH
10.11.1 Overview
10.11.2 Financial Performance
10.11.3 Product Outlook
10.11.4 Key Developments

10.12 Molecular Biology Resources, Inc.
10.12.1 Overview
10.12.2 Financial Performance
10.12.3 Product Outlook
10.12.4 Key Developments

11 Appendix
11.1 Related Reports